|
ROCKVILLE, Md., Jun 24, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has
completed separate international sales and deliveries of BioThrax(R)
(Anthrax Vaccine Adsorbed) to governments of several allied nations. The
company's international sales efforts have resultedin these
sales of an undisclosed number of BioThrax doses for aggregate revenue
of approximately $2.3 million in the second quarter.
"Emergent recognizes that governments play a key role in protecting
citizens against the growing threat of bioterrorism," said Allen Shofe,
senior vice president public affairs of Emergent BioSolutions. "As the
maker of the only U.S. FDA-licensed anthrax vaccine, and in line with
our corporate mission to protect life, we are honored to support such
biopreparedness efforts of allied international governments."
About BioThrax
BioThrax is the only U.S. FDA-licensed vaccine for the prevention of
anthrax infection. It is indicated for the active immunization of adults
who are at high risk of exposure to anthrax. BioThrax is manufactured
from a culture filtrate, made from a non-virulent strain of Bacillus
anthracis. Since 1998, the U.S. government has procured over 42
million doses of BioThrax. During that time period, more than 9.5
million doses have been administered to nearly 2.4 million military
personnel. For full prescribing information, please visit www.biothrax.com/prescribinginformation_biothrax_us.pdf.
Important Safety Information for BioThrax(R)
The most common (>10%) local (injection-site) adverse reactions observed
in clinical studies were tenderness, pain, erythema and arm motion
limitation. The most common (>5%) systemic adverse reactions were muscle
aches, fatigue and headache. Serious allergic reactions, including
anaphylactic shock, have been observed during post-marketing
surveillance in individuals receiving BioThrax.
Pregnant women should not be vaccinated unless the potential benefits of
vaccination have been determined to outweigh the potential risk to the
fetus. If BioThrax is used during pregnancy, or if the patient becomes
pregnant during the immunization series, the patient should be apprised
of the potential hazard to the fetus. This product should be
administered with caution to persons with a possible history of latex
sensitivity since the vial stopper contains dry natural rubber.
Vaccination with BioThrax should be avoided by individuals with a
history of anaphylactic or anaphylactic-like reaction following a
previous dose of BioThrax.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including any potential future securities
offering, our expected revenue growth and net earnings for 2010, and any
other statements containing the words "believes", "expects",
"anticipates", "plans", "estimates" and similar expressions, are
forward-looking statements. There are a number of important factors that
could cause the company's actual results to differ materially from those
indicated by such forward-looking statements, including appropriations
for BioThrax(R) procurement; our ability to obtain new BioThrax(R)
sales contracts; our plans to pursue label expansions and improvements
for BioThrax(R); our plans to expand our manufacturing
facilities and capabilities; the rate and degree of market acceptance
and clinical utility of our products; the success of our ongoing and
planned development programs, preclinical studies and clinical trials;
and other factors identified in the company's Quarterly Report on Form
10-Q for the quarter ended March 31, 2010 and subsequent reports filed
with the SEC. The company disclaims any intention or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this press release.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
BurrowsR@ebsi.com
or
Media:
Tracey Schmitt, 301-795-1800
Vice President, Corporate Communications
SchmittT@ebsi.com |